DSM-Firmenich stock downgraded by Deutsche Bank as target rises
Published on 11/21/2026 at 11:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDeutsche Bank turns more cautious
- Deutsche Bank lowered its rating on DSM-Firmenich from Buy to Hold on November 16.
- The broker raised its price target while pointing to execution against the group's 2028 goals.
- DSM-Firmenich stock lost 1.33 percent on Euronext Amsterdam over the week.
Deutsche Bank lowered its rating on DSM-Firmenich from Buy to Hold on Monday, November 16, while raising its price target from 110 euros to 112 euros. Investing.com said the broker sees a more balanced risk-reward profile after the stock's re-rating.
Valuation puts execution in focus
Deutsche Bank said further upside depends on delivery against DSM-Firmenich's 2028 objectives. Analyst Virginie Boucher-Ferte linked the outlook to organic sales growth of 5 to 7 percent and an EBITDA margin of 22 to 23 percent in 2028, while the broker identified risks to both goals.
The bank still expects solid organic growth and margin expansion in 2027. Its forecasts were 3 percent above consensus, while modest earnings-per-share upgrades amounted to around 1 percent.
Weekly share performance
On Euronext Amsterdam, DSM-Firmenich stock closed at 104.20 euros on Friday, November 20, down 1.33 percent from the 105.60-euro close on Friday, November 13. The stock traded at 103.30 euros on Lang & Schwarz at 11:54 CET on Saturday, November 21, 2026.
DSM-Firmenich stock at a glance
- Company: DSM-Firmenich AG
- ISIN: CH1216478797
- Symbol: DSFIR
- Home exchange: Euronext Amsterdam
- Lang & Schwarz quote: 103.30 euros on November 21, 2026 at 11:54 CET
- Weekly change: -1.33 percent, from 105.60 euros on November 13 to 104.20 euros on November 20, 2026
European equities remained the broader market backdrop for the week. Current market reports provide further market context.
